Thromb Haemost 1994; 71(01): 091-094
DOI: 10.1055/s-0038-1642389
Review Article
Schattauer GmbH Stuttgart

Ticlopidine Facilitates the Deaggregation of Human Platelets Aggregated by Thrombin

M Cattaneo
The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, IRCCS Maggiore Hospital and University of Milano, Italy
,
B Akkawat
The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, IRCCS Maggiore Hospital and University of Milano, Italy
,
R L Kinlough-Rathbone
1   Department of Pathology, McMaster University, Hamilton, Ontario
,
M A Packham
2   Department of Biochemistry, University of Toronto, Toronto, Ontario
,
C Cimminiello
3   Medicina IV, San Carlo Hospital, Milano, Italy
,
P M Mannucci
The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, IRCCS Maggiore Hospital and University of Milano, Italy
› Author Affiliations
Further Information

Publication History

Received: 02 February 1993

Accepted after revision 05 October 1993

Publication Date:
12 July 2018 (online)

Preview

Summary

Normal human platelets aggregated by thrombin undergo the release reaction and are not readily deaggregated by the combination of inhibitors hirudin, prostaglandin E1 (PGE1) and chymotrypsin. Released adenosine diphosphate (ADP) plays an important role in the stabilization of thrombin-induced human platelet aggregates. Since ticlopidine inhibits the platelet responses to ADP, we studied thrombin-induced aggregation and deaggregation of 14C-serotonin-labeled platelets from 12 patients with cardiovascular disease before and 7 days after the oral administration of ticlopidine, 250 mg b.i.d. Before and after ticlopidine, platelets stimulated with 1 U/ml thrombin aggregated, released about 80–90% 14C-serotinin and did not deaggregate spontaneously within 5 min from stimulation. Before ticlopidine, hirudin (5× the activity of thrombin) and PGE1 (10 μmol/1) plus chymotrypsin (10 U/ml) or plasmin (0.06 U/ml), added at the peak of platelet aggregation, caused slight or no platelet deaggregation. After ticlopidine, the extent of platelet deaggregation caused by the same inhibitors was significantly greater than before ticlopidine. The addition of ADP (10 μmol/1) to platelet suspensions 5 s after thrombin did not prevent the deaggregation of ticlopidine-treated platelets. Thus, ticlopidine facilitates the deaggregation of thrombin-induced human platelet aggregates, most probably because it inhibits the effects of ADP on platelets.